Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

NCT04379635 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

453

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Tislelizumab
DRUG: Cisplatin injection
DRUG: Paclitaxel injection
DRUG: Pemetrexed Disodium
DRUG: Placebos
DRUG: Carboplatin

Sponsor

BeiGene